Alt det, du går op i, samlet ét sted
Følg feeds: blogs, nyheder, RSS og meget mere. En nem måde at læse og få overblik over det indhold, du selv vælger.
Få FeederRSS-feeds om Medicinalindustri
De RSS-feeds om Medicinalindustri, som Feeder-brugere følger mest, herunder ClinicalTrials.gov: NCFB | Last update posted in the last 14 days, ClinicalTrials.gov: Amyloidosis | Phase: 1, 2, 3 | Interventional studies | Last update posted in the last 14 days og Bayer Global PR | GU. Kopiér en feed-URL, eller følg dem gratis i Feeder.
Relaterede emner
RSS-feeds om Sundhed RSS-feeds om Onkologi RSS-feeds om Kliniske forsøg RSS-feeds om Medicinsk forskning RSS-feeds om Mental sundhed RSS-feeds om Psykologi RSS-feeds om Folkesundhed
Foreslå en rettelseClinicalTrials.gov: NCFB | Last update posted in the last 14 days
Studies found on ClinicalTrials.gov by a search of: NCFB | Last update posted in the last 14 days
ClinicalTrials.gov: Amyloidosis | Phase: 1, 2, 3 | Interventional studies | Last update posted in the last 14 days
Studies found on ClinicalTrials.gov by a search of: Amyloidosis | Phase: 1, 2, 3 | Interventional studies | Last update posted in the last 14 days
Nxera Pharma | IR English (Narcolepsy)
Nxera Pharma Investors information IR News page.
Business Wire - News by Company: Bayer
Business Wire - The global leader in news distribution
ClinicalTrials.gov: SKB410 | Last update posted in the last 14 days
Studies found on ClinicalTrials.gov by a search of: SKB410 | Last update posted in the last 14 days
ClinicalTrials.gov: CRB-701 | Last update posted in the last 14 days
Studies found on ClinicalTrials.gov by a search of: CRB-701 | Last update posted in the last 14 days
ClinicalTrials.gov: LY4052031 | Last update posted in the last 14 days
Studies found on ClinicalTrials.gov by a search of: LY4052031 | Last update posted in the last 14 days
ClinicalTrials.gov: MK-3120 | Last update posted in the last 14 days
Studies found on ClinicalTrials.gov by a search of: MK-3120 | Last update posted in the last 14 days
ClinicalTrials.gov: AKY-1189 | Last update posted in the last 14 days
Studies found on ClinicalTrials.gov by a search of: AKY-1189 | Last update posted in the last 14 days
ClinicalTrials.gov: Other terms: RSV vaccine | Last update posted in the last 14 days
Studies found on ClinicalTrials.gov by a search of: Other terms: RSV vaccine | Last update posted in the last 14 days
ClinicalTrials.gov: Homozygous Familial Hypercholesterolemia | Last update posted in the last 14 days
Studies found on ClinicalTrials.gov by a search of: Homozygous Familial Hypercholesterolemia | Last update posted in the last 14 days
ClinicalTrials.gov: Other terms: Pfizer | Last update posted in the last 14 days
Studies found on ClinicalTrials.gov by a search of: Other terms: Pfizer | Last update posted in the last 14 days
ClinicalTrials.gov: Other terms: Sanofi | Last update posted in the last 14 days
Studies found on ClinicalTrials.gov by a search of: Other terms: Sanofi | Last update posted in the last 14 days
J&J PR | GU
Explore all Johnson & Johnson published press releases by date and/or topic of news.
Global News | Astellas | GU
Explore Astellas’ global press releases and discover the latest news and updates about Astellas.
Bayer | LinkedIn
Bayer | 6,769,296 followers on LinkedIn. Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. We design our products and services to serve the most essential human needs of health and nutrition. At the same time, we strive to address some of the world’s biggest challenges presented by a growing and aging global population.
Bayer UK | LinkedIn
Bayer UK | 7,724 followers on LinkedIn. Bayer in the UK | Bayer is a global life science company with core interests in healthcare and agriculture. At Bayer, our mission of “Health for All, Hunger for None” drives our commitment to addressing societal and environmental needs, benefiting people and improving their quality of life. Through research and innovation, we aim to reimagine how we care for ourselves, and one another, by empowering everyday health, improving approaches to patient care,